Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma

Seventeen patients with malignant mesothelioma were treated in a phase II study with carboplatin, a cisplatin analogue without significant nephrotoxicity or neurotoxicity. The drug was given in a dose of 300-400 mg/m2 by i.v. infusion, repeating at 28-day intervals. One patient achieved a complete c...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1986-01, Vol.18 (3), p.284-285
Main Authors: MBIDDE, E. K, HARLAND, S. J, HILARY CALVERT, A, SMITH, I. E
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Carboplatin
Chemotherapy
Drug Evaluation
Female
Humans
Infusions, Intravenous
Male
Medical sciences
Mesothelioma - drug therapy
Middle Aged
Organoplatinum Compounds - administration & dosage
Organoplatinum Compounds - adverse effects
Organoplatinum Compounds - therapeutic use
Peritoneal Neoplasms - drug therapy
Pharmacology. Drug treatments
Pleural Neoplasms - drug therapy
Time Factors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Seventeen patients with malignant mesothelioma were treated in a phase II study with carboplatin, a cisplatin analogue without significant nephrotoxicity or neurotoxicity. The drug was given in a dose of 300-400 mg/m2 by i.v. infusion, repeating at 28-day intervals. One patient achieved a complete clinical and radiological remission of 15 months' duration, and a second patient achieved a partial response of 11 months' duration (overall response rate 12%; overall response rate in previously untreated patients 20%). Four other previously untreated patients achieved symptomatic relief. Treatment was well tolerated without severe side-effects. Carboplatin, like most other cytotoxic drugs, is active only in a small minority of patients with mesothelioma, but its ability to achieve occasional good responses and frequent symptomatic relief, combined with low toxicity, may justify a short therapeutic trial in patients whose tumour is symptomatic.
ISSN:0344-5704
1432-0843
DOI:10.1007/BF00273404